Effect of treatment with prostaglandin E1 and N-acetylcysteine on pediatric liver transplant recipients: A single-center study

Pediatric Transplantation

Volumn 5, Issue 4, 2001, Pages 274-278

  Bucuvalas, John C ^a,b   Ryckman, Frederick C ^a   Krug, Susan ^a   Alonso, Maria P ^a   Balistreri, William F ^a   Kotagal, Uma ^b  

^a Children’s Hospital Research Foundation ^*  (United States)

^b CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

Anti oxidants; N acetylcysteine; Non immune mediated injury; Pediatric liver transplantation; Prostaglandin

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE SODIUM SUCCINATE; PROSTAGLANDIN E1; TACROLIMUS;

ARTICLE; BILE LEAKAGE; BRONCHOSPASM; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; ENZYME BLOOD LEVEL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; LENGTH OF STAY; LIVER TRANSPLANTATION; MALE; PEDIATRIC SURGERY; POSTOPERATIVE COMPLICATION; REPERFUSION; REPERFUSION INJURY; STOMACH OBSTRUCTION; SURVIVAL RATE; THROMBOSIS; TREATMENT OUTCOME;

ACETYLCYSTEINE; ALPROSTADIL; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; FREE RADICAL SCAVENGERS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; LIVER TRANSPLANTATION; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0034933440     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2001.005004274.x     Document Type: Article

References (34)

1. Risk factors and outcomes after pediatric liver transplantation
2. Long-term results of pediatric liver transplantation: An analysis of 569 transplants
3. A double-blind, randomized, placebo-controlled trial of prostaglandin E1 in liver transplantation
4. Prostaglandin E1 administration following orthotopic liver transplantation: A randomized prospective multicenter trial
5. Prostaglandin E1 for the treatment of primary non-function of the donor organ in liver transplantation
6. Prostaglandin therapy in primary liver graft nonfunction after orthotopic transplantation
7. Reduction of primary nonfunction with prostaglandin E1 after clinical liver transplantation
8. Efficacy of N-acetylcysteine as a hepatoprotective agent in liver transplantation: An experimental study
9. The efficacy of N-acetylcysteine as a hepatoprotective agent in liver transplantation
10. Does N-acetylcysteine improve hemodynamics and graft function in liver transplantation?
11. Impact of N-acetylcysteine on the hepatic microcirculation after orthotopic liver transplantation
12. N-acetylcysteine improves indocyanine green extraction and oxygen transport during hepatic dysfunction
13. Treatment of primary liver graft non-function with prostaglandin E1 results in increased graft and patient survival
14. Prostaglandin E1 analogs do not improve renal function among either transplant or nontransplant patients: No further trials required
15. Efficacy of oral N-acetylcysteine in the treatment of acetoaminophen overdose: Analysis of the National Multicenter Study (1976-85)
16. Neonatal hemochromatosis: Outcomes of pharmacologic and surgical therapies
17. Treatment of primary liver graft nonfunction with prostaglandin E1
18. Gastric-outlet obstruction induced by prostaglandin therapy in neonates
19. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals
20. Portal and systemic haemodynamic action of N-acetylcysteine in patients with stable cirrhosis
21. Anaphylactoid reaction to intravenous acetylcysteine associated with electrocardiographic abnormalities
22. Terminology for hepatic allograft rejection
23. Early hepatocyte, endothelial, and bile duct cell injury after pediatric liver transplantation from cadaveric or living-related donors
24. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells
25. Reperfusion injury, antioxidants and hemodynamics during orthotopic liver transplantation
26. Molecular therapies for vascular diseases
27. Modification of vascular responses in xenotransplantation: Inflammation and apoptosis
28. Accommodation of vascularized xenografts: Expression of 'protective genes' by donor endothelial cells in a host Th2 cytokine environment
29. Predictors of the cost of liver transplantation
30. The impact of surgical complications after liver transplantation on resource utilization
31. Resource utilization in liver transplantation: Effects of patient characteristics and clinical practice
32. Payer status, but not race, affects the cost of liver transplantation
33. The influence of clinical variables on hospital costs after orthotopic liver transplantation